ID   DPOD1_HUMAN             Reviewed;        1107 AA.
AC   P28340; Q8NER3; Q96H98;
DT   01-DEC-1992, integrated into UniProtKB/Swiss-Prot.
DT   19-JUL-2004, sequence version 2.
DT   10-MAY-2017, entry version 178.
DE   RecName: Full=DNA polymerase delta catalytic subunit;
DE            EC=2.7.7.7;
DE            EC=3.1.11.-;
DE   AltName: Full=DNA polymerase subunit delta p125;
GN   Name=POLD1; Synonyms=POLD;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT TRP-30.
RC   TISSUE=Hepatoma;
RX   PubMed=1722322; DOI=10.1073/pnas.88.24.11197;
RA   Chung D.W., Zhang J., Tan C.-K., Davie E.W., So A.G., Downey K.M.;
RT   "Primary structure of the catalytic subunit of human DNA polymerase
RT   delta and chromosomal location of the gene.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:11197-11201(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], VARIANTS HIS-119 AND ASN-173, AND
RP   INDUCTION BY SERUM.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=1542570; DOI=10.1093/nar/20.4.735;
RA   Yang C.-L., Chang L.-S., Zhang P., Hao H., Zhu L., Toomey N.L.,
RA   Lee M.Y.W.T.;
RT   "Molecular cloning of the cDNA for the catalytic subunit of human DNA
RT   polymerase delta.";
RL   Nucleic Acids Res. 20:735-745(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS HIS-19; TRP-30;
RP   HIS-119; ASN-173; HIS-177; HIS-849 AND GLN-1086.
RG   NIEHS SNPs program;
RL   Submitted (JUL-2002) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT HIS-119.
RC   TISSUE=Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   INTERACTION WITH POLD2 AND PCNA.
RX   PubMed=11328591; DOI=10.1093/oxfordjournals.jbchem.a002909;
RA   Shikata K., Ohta S., Yamada K., Obuse C., Yoshikawa H., Tsurimoto T.;
RT   "The human homologue of fission Yeast cdc27, p66, is a component of
RT   active human DNA polymerase delta.";
RL   J. Biochem. 129:699-708(2001).
RN   [6]
RP   INTERACTION WITH POLD3, AND SUBCELLULAR LOCATION.
RX   PubMed=11595739; DOI=10.1074/jbc.M106990200;
RA   Ducoux M., Urbach S., Baldacci G., Huebscher U., Koundrioukoff S.,
RA   Christensen J., Hughes P.;
RT   "Mediation of proliferating cell nuclear antigen (PCNA)-dependent DNA
RT   replication through a conserved p21(Cip1)-like PCNA-binding motif
RT   present in the third subunit of human DNA polymerase delta.";
RL   J. Biol. Chem. 276:49258-49266(2001).
RN   [7]
RP   INTERACTION WITH PCNA AND POLD4, AND CHARACTERIZATION OF POL-DELTA2
RP   AND POL-DELTA4 COMPLEXES.
RX   PubMed=12403614; DOI=10.1021/bi0262707;
RA   Xie B., Mazloum N., Liu L., Rahmeh A., Li H., Lee M.Y.;
RT   "Reconstitution and characterization of the human DNA polymerase delta
RT   four-subunit holoenzyme.";
RL   Biochemistry 41:13133-13142(2002).
RN   [8]
RP   INTERACTION WITH POLD2 AND POLDIP2, AND STIMULATION BY PCNA.
RX   PubMed=12522211; DOI=10.1074/jbc.M208694200;
RA   Liu L., Rodriguez-Belmonte E.M., Mazloum N., Xie B., Lee M.Y.W.T.;
RT   "Identification of a novel protein, PDIP38, that interacts with the
RT   p50 subunit of DNA polymerase delta and proliferating cell nuclear
RT   antigen.";
RL   J. Biol. Chem. 278:10041-10047(2003).
RN   [9]
RP   INTERACTION WITH WRNIP1.
RX   PubMed=15670210; DOI=10.1111/j.1365-2443.2004.00812.x;
RA   Tsurimoto T., Shinozaki A., Yano M., Seki M., Enomoto T.;
RT   "Human Werner helicase interacting protein 1 (WRNIP1) functions as a
RT   novel modulator for DNA polymerase delta.";
RL   Genes Cells 10:13-22(2005).
RN   [10]
RP   FUNCTION, AND INTERACTION WITH POLD2; POLD4 AND PCNA.
RX   PubMed=16510448; DOI=10.1074/jbc.M600322200;
RA   Li H., Xie B., Zhou Y., Rahmeh A., Trusa S., Zhang S., Gao Y.,
RA   Lee E.Y., Lee M.Y.;
RT   "Functional roles of p12, the fourth subunit of human DNA polymerase
RT   delta.";
RL   J. Biol. Chem. 281:14748-14755(2006).
RN   [11]
RP   IDENTIFICATION IN POL-DELTA COMPLEX.
RX   PubMed=17317665; DOI=10.1074/jbc.M610356200;
RA   Zhang S., Zhou Y., Trusa S., Meng X., Lee E.Y., Lee M.Y.;
RT   "A novel DNA damage response: rapid degradation of the p12 subunit of
RT   dna polymerase delta.";
RL   J. Biol. Chem. 282:15330-15340(2007).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [13]
RP   FUNCTION, MUTAGENESIS OF ASP-402, CHARACTERIZATION OF POL-DELTA3 AND
RP   POL-DELTA4, AND ENZYME REGULATION.
RX   PubMed=19074196; DOI=10.1093/nar/gkn1000;
RA   Meng X., Zhou Y., Zhang S., Lee E.Y., Frick D.N., Lee M.Y.;
RT   "DNA damage alters DNA polymerase delta to a form that exhibits
RT   increased discrimination against modified template bases and
RT   mismatched primers.";
RL   Nucleic Acids Res. 37:647-657(2009).
RN   [14]
RP   FUNCTION, CHARACTERIZATION OF POL-DELTA3 AND POL-DELTA4,
RP   BIOPHYSICOCHEMICAL PROPERTIES, AND MUTAGENESIS OF ASP-402.
RX   PubMed=20334433; DOI=10.1021/bi100042b;
RA   Meng X., Zhou Y., Lee E.Y., Lee M.Y., Frick D.N.;
RT   "The p12 subunit of human polymerase delta modulates the rate and
RT   fidelity of DNA synthesis.";
RL   Biochemistry 49:3545-3554(2010).
RN   [15]
RP   FUNCTION IN NUCLEOTIDE EXCISION REPAIR, AND SUBCELLULAR LOCATION.
RX   PubMed=20227374; DOI=10.1016/j.molcel.2010.02.009;
RA   Ogi T., Limsirichaikul S., Overmeer R.M., Volker M., Takenaka K.,
RA   Cloney R., Nakazawa Y., Niimi A., Miki Y., Jaspers N.G.,
RA   Mullenders L.H., Yamashita S., Fousteri M.I., Lehmann A.R.;
RT   "Three DNA polymerases, recruited by different mechanisms, carry out
RT   NER repair synthesis in human cells.";
RL   Mol. Cell 37:714-727(2010).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [17]
RP   SUBCELLULAR LOCATION, IDENTIFICATION IN POLD COMPLEX, AND
RP   DEVELOPMENTAL STAGE.
RX   PubMed=22801543; DOI=10.4161/cc.21280;
RA   Chea J., Zhang S., Zhao H., Zhang Z., Lee E.Y., Darzynkiewicz Z.,
RA   Lee M.Y.;
RT   "Spatiotemporal recruitment of human DNA polymerase delta to sites of
RT   UV damage.";
RL   Cell Cycle 11:2885-2895(2012).
RN   [18]
RP   FUNCTION IN OKAZAKI FRAGMENT PROCESSING.
RX   PubMed=24035200; DOI=10.1016/j.dnarep.2013.08.008;
RA   Lin S.H., Wang X., Zhang S., Zhang Z., Lee E.Y., Lee M.Y.;
RT   "Dynamics of enzymatic interactions during short flap human Okazaki
RT   fragment processing by two forms of human DNA polymerase delta.";
RL   DNA Repair 12:922-935(2013).
RN   [19]
RP   POL-DELTA3 COMPLEX EXPRESSION DURING CELL CYCLE.
RX   PubMed=23913683; DOI=10.1074/jbc.M113.490466;
RA   Zhang S., Zhao H., Darzynkiewicz Z., Zhou P., Zhang Z., Lee E.Y.,
RA   Lee M.Y.;
RT   "A novel function of CRL4(Cdt2): regulation of the subunit structure
RT   of DNA polymerase delta in response to DNA damage and during the S
RT   phase.";
RL   J. Biol. Chem. 288:29550-29561(2013).
RN   [20]
RP   FUNCTION, AND INTERACTION WITH PCNA.
RX   PubMed=24022480; DOI=10.1074/jbc.C113.505586;
RA   Terai K., Shibata E., Abbas T., Dutta A.;
RT   "Degradation of p12 subunit by CRL4Cdt2 E3 ligase inhibits fork
RT   progression after DNA damage.";
RL   J. Biol. Chem. 288:30509-30514(2013).
RN   [21]
RP   TISSUE SPECIFICITY, AND VARIANT MDPL SER-605 DEL.
RX   PubMed=23770608; DOI=10.1038/ng.2670;
RA   Weedon M.N., Ellard S., Prindle M.J., Caswell R., Allen H.L., Oram R.,
RA   Godbole K., Yajnik C.S., Sbraccia P., Novelli G., Turnpenny P.,
RA   McCann E., Goh K.J., Wang Y., Fulford J., McCulloch L.J., Savage D.B.,
RA   O'Rahilly S., Kos K., Loeb L.A., Semple R.K., Hattersley A.T.;
RT   "An in-frame deletion at the polymerase active site of POLD1 causes a
RT   multisystem disorder with lipodystrophy.";
RL   Nat. Genet. 45:947-950(2013).
RN   [22]
RP   METHYLATION [LARGE SCALE ANALYSIS] AT ARG-19, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Colon carcinoma;
RX   PubMed=24129315; DOI=10.1074/mcp.O113.027870;
RA   Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V.,
RA   Aguiar M., Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C.,
RA   Vemulapalli V., Bedford M.T., Comb M.J.;
RT   "Immunoaffinity enrichment and mass spectrometry analysis of protein
RT   methylation.";
RL   Mol. Cell. Proteomics 13:372-387(2014).
RN   [23]
RP   INTERACTION WITH PCNA.
RX   PubMed=24939902; DOI=10.1093/nar/gku533;
RA   Cazzalini O., Sommatis S., Tillhon M., Dutto I., Bachi A., Rapp A.,
RA   Nardo T., Scovassi A.I., Necchi D., Cardoso M.C., Stivala L.A.,
RA   Prosperi E.;
RT   "CBP and p300 acetylate PCNA to link its degradation with nucleotide
RT   excision repair synthesis.";
RL   Nucleic Acids Res. 42:8433-8448(2014).
RN   [24]
RP   FUNCTION IN BIR.
RX   PubMed=24310611; DOI=10.1126/science.1243211;
RA   Costantino L., Sotiriou S.K., Rantala J.K., Magin S., Mladenov E.,
RA   Helleday T., Haber J.E., Iliakis G., Kallioniemi O.P.,
RA   Halazonetis T.D.;
RT   "Break-induced replication repair of damaged forks induces genomic
RT   duplications in human cells.";
RL   Science 343:88-91(2014).
RN   [25]
RP   VARIANT CRCS10 ASN-478, AND VARIANTS ASP-145; HIS-461; LEU-787;
RP   HIS-808 AND THR-864.
RX   PubMed=23263490; DOI=10.1038/ng.2503;
RG   CORGI Consortium;
RG   WGS500 Consortium;
RA   Palles C., Cazier J.B., Howarth K.M., Domingo E., Jones A.M.,
RA   Broderick P., Kemp Z., Spain S.L., Guarino Almeida E., Salguero I.,
RA   Sherborne A., Chubb D., Carvajal-Carmona L.G., Ma Y., Kaur K.,
RA   Dobbins S., Barclay E., Gorman M., Martin L., Kovac M.B., Humphray S.,
RA   Lucassen A., Holmes C.C., Bentley D., Donnelly P., Taylor J.,
RA   Petridis C., Roylance R., Sawyer E.J., Kerr D.J., Clark S., Grimes J.,
RA   Kearsey S.E., Thomas H.J., McVean G., Houlston R.S., Tomlinson I.;
RT   "Germline mutations affecting the proofreading domains of POLE and
RT   POLD1 predispose to colorectal adenomas and carcinomas.";
RL   Nat. Genet. 45:136-144(2013).
RN   [26]
RP   VARIANT CRCS10 PRO-474.
RX   PubMed=24501277; DOI=10.1093/hmg/ddu058;
RA   Valle L., Hernandez-Illan E., Bellido F., Aiza G., Castillejo A.,
RA   Castillejo M.I., Navarro M., Segui N., Vargas G., Guarinos C.,
RA   Juarez M., Sanjuan X., Iglesias S., Alenda C., Egoavil C., Segura A.,
RA   Juan M.J., Rodriguez-Soler M., Brunet J., Gonzalez S., Jover R.,
RA   Lazaro C., Capella G., Pineda M., Soto J.L., Blanco I.;
RT   "New insights into POLE and POLD1 germline mutations in familial
RT   colorectal cancer and polyposis.";
RL   Hum. Mol. Genet. 23:3506-3512(2014).
CC   -!- FUNCTION: As the catalytic component of the trimeric (Pol-delta3
CC       complex) and tetrameric DNA polymerase delta complexes (Pol-delta4
CC       complex), plays a crucial role in high fidelity genome
CC       replication, including in lagging strand synthesis, and repair.
CC       Exhibits both DNA polymerase and 3'- to 5'-exonuclease activities
CC       (PubMed:16510448, PubMed:19074196, PubMed:20334433,
CC       PubMed:24035200, PubMed:24022480). Requires the presence of
CC       accessory proteins POLD2, POLD3 and POLD4 for full activity.
CC       Depending upon the absence (Pol-delta3) or the presence of POLD4
CC       (Pol-delta4), displays differences in catalytic activity. Most
CC       notably, expresses higher proofreading activity in the context of
CC       Pol-delta3 compared with that of Pol-delta4 (PubMed:19074196,
CC       PubMed:20334433). Although both Pol-delta3 and Pol-delta4 process
CC       Okazaki fragments in vitro, Pol-delta3 may be better suited to
CC       fulfill this task, exhibiting near-absence of strand displacement
CC       activity compared to Pol-delta4 and stalling on encounter with the
CC       5'-blocking oligonucleotides. Pol-delta3 idling process may avoid
CC       the formation of a gap, while maintaining a nick that can be
CC       readily ligated (PubMed:24035200). Along with DNA polymerase
CC       kappa, DNA polymerase delta carries out approximately half of
CC       nucleotide excision repair (NER) synthesis following UV
CC       irradiation (PubMed:20227374). Under conditions of DNA replication
CC       stress, in the presence of POLD3 and POLD4, may catalyze the
CC       repair of broken replication forks through break-induced
CC       replication (BIR) (PubMed:24310611). Involved in the translesion
CC       synthesis (TLS) of templates carrying O6-methylguanine or abasic
CC       sites (PubMed:19074196). {ECO:0000269|PubMed:16510448,
CC       ECO:0000269|PubMed:19074196, ECO:0000269|PubMed:20227374,
CC       ECO:0000269|PubMed:20334433, ECO:0000269|PubMed:24022480,
CC       ECO:0000269|PubMed:24035200, ECO:0000269|PubMed:24310611}.
CC   -!- CATALYTIC ACTIVITY: Deoxynucleoside triphosphate + DNA(n) =
CC       diphosphate + DNA(n+1).
CC   -!- COFACTOR:
CC       Name=[4Fe-4S] cluster; Xref=ChEBI:CHEBI:49883;
CC         Evidence={ECO:0000250};
CC       Note=Binds 1 [4Fe-4S] cluster. {ECO:0000250};
CC   -!- ENZYME REGULATION: Regulated by alteration of quaternary
CC       structure. Exhibits burst rates of DNA synthesis are about 5 times
CC       faster in the presence of POLD4 (Pol-delta4 complex) than in its
CC       absence (Pol-delta3 complex), while the affinity of the enzyme for
CC       its DNA and dNTP substrates appears unchanged. The Pol-delta3
CC       complex is more likely to proofread DNA synthesis because it
CC       cleaves single-stranded DNA twice as fast and transfers mismatched
CC       DNA from the polymerase to the exonuclease sites 9 times faster
CC       compared to the Pol-delta3 complex. Pol-delta3 also extends
CC       mismatched primers 3 times more slowly in the absence of POLD4.
CC       The conversion of Pol-delta4 into Pol-delta3 is induced by
CC       genotoxic stress or by replication stress leading POLD4
CC       degradation (PubMed:19074196, PubMed:20334433). Stimulated in the
CC       presence of PCNA (PubMed:11328591, PubMed:12403614,
CC       PubMed:12522211, PubMed:16510448, PubMed:24022480,
CC       PubMed:24939902). This stimulation is further increased in the
CC       presence of KCTD13/PDIP1, most probably via direct interaction
CC       between KCTD13 and POLD2 (By similarity).
CC       {ECO:0000250|UniProtKB:P28339, ECO:0000269|PubMed:11328591,
CC       ECO:0000269|PubMed:12403614, ECO:0000269|PubMed:12522211,
CC       ECO:0000269|PubMed:16510448, ECO:0000269|PubMed:19074196,
CC       ECO:0000269|PubMed:20334433, ECO:0000269|PubMed:24022480,
CC       ECO:0000269|PubMed:24939902}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         Note=kcat is 87 sec(-1) for DNA synthesis by Pol-delta4 and 19
CC         sec(-1) for Pol-delta3. kcat for exonuclease activity determined
CC         using a 26mer/40mer duplex DNA gives a value of 0.003 sec(-1)
CC         for Pol-delta4 and 0.026 sec(-1) for Pol-delta3. When using a
CC         26mer/40mer with a T:G mismatch at the primer terminus, the
CC         switching rates from the polymerase to the exonuclease site for
CC         Pol-delta4 and Pol-delta3 are increased 20- and 10-fold,
CC         respectively, but the rate constant for Pol-delta3 is still 5-
CC         fold faster than that for Pol-delta4.;
CC   -!- SUBUNIT: Component of the tetrameric DNA polymerase delta complex
CC       (Pol-delta4), which consists of POLD1/p125, POLD2/p50,
CC       POLD3/p66/p68 and POLD4/p12, with POLD1 bearing both DNA
CC       polymerase and 3' to 5' proofreading exonuclease activities
CC       (PubMed:11595739, PubMed:12522211, PubMed:17317665,
CC       PubMed:22801543). Within Pol-delta4, directly interacts with POLD2
CC       and POLD4 (PubMed:11328591, PubMed:12403614, PubMed:16510448).
CC       Following genotoxic stress by DNA-damaging agents, such as
CC       ultraviolet light and methyl methanesulfonate, or by replication
CC       stress induced by treatment with hydroxyurea or aphidicolin, Pol-
CC       delta4 is converted into a trimeric form of the complex (Pol-
CC       delta3) by POLD4 degradation. Pol-delta3 is the major form at S
CC       phase replication sites and DNA damage sites (PubMed:22801543,
CC       PubMed:17317665). POLD1 displays different catalytic properties
CC       depending upon the complex it is found in (PubMed:17317665). It
CC       exhibits higher proofreading activity and fidelity than Pol-
CC       delta4, making it particularly well suited to respond to DNA
CC       damage (PubMed:19074196, PubMed:20334433). Directly interacts with
CC       PCNA, as do POLD3 and POLD4; this interaction stimulates Pol-
CC       delta4 polymerase activity (PubMed:11328591, PubMed:12403614,
CC       PubMed:12522211, PubMed:16510448, PubMed:24022480,
CC       PubMed:24939902). As POLD2 and POLD4, directly interacts with
CC       WRNIP1; this interaction stimulates DNA polymerase delta-mediated
CC       DNA synthesis, independently of the presence of PCNA. This
CC       stimulation may be due predominantly to an increase of initiation
CC       frequency and also to increased processivity (PubMed:15670210).
CC       Also observed as a dimeric complex with POLD2 (Pol-delta2
CC       complex). Pol-delta2 is relatively insensitive to the PCNA
CC       stimulation (2-5-fold) compared to Pol-delta4 that is stimulated
CC       by over 50-fold (PubMed:12403614). The DNA polymerase delta
CC       complex interacts with POLDIP2; this interaction is probably
CC       mediated through direct binding to POLD2 (PubMed:12522211).
CC       {ECO:0000269|PubMed:11328591, ECO:0000269|PubMed:11595739,
CC       ECO:0000269|PubMed:12403614, ECO:0000269|PubMed:12522211,
CC       ECO:0000269|PubMed:15670210, ECO:0000269|PubMed:16510448,
CC       ECO:0000269|PubMed:17317665, ECO:0000269|PubMed:19074196,
CC       ECO:0000269|PubMed:20334433, ECO:0000269|PubMed:22801543,
CC       ECO:0000269|PubMed:24022480, ECO:0000269|PubMed:24939902}.
CC   -!- INTERACTION:
CC       P12004:PCNA; NbExp=3; IntAct=EBI-716569, EBI-358311;
CC       P49005:POLD2; NbExp=10; IntAct=EBI-716569, EBI-372354;
CC       Q9HCU8:POLD4; NbExp=11; IntAct=EBI-716569, EBI-864968;
CC       Q9NYB0:TERF2IP; NbExp=2; IntAct=EBI-716569, EBI-750109;
CC       Q96S55:WRNIP1; NbExp=2; IntAct=EBI-716569, EBI-2513471;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:11595739,
CC       ECO:0000269|PubMed:20227374, ECO:0000269|PubMed:22801543}.
CC       Note=Colocalizes with PCNA and POLD3 at S phase replication sites
CC       (PubMed:11595739). After UV irradiation, recruited to DNA damage
CC       sites within 2 hours, independently on the cell cycle phase, nor
CC       on PCNA ubiquitination. This recruitement requires POLD3, PCNA and
CC       RFC1-replication factor C complex (PubMed:20227374,
CC       PubMed:22801543). {ECO:0000269|PubMed:11595739,
CC       ECO:0000269|PubMed:20227374, ECO:0000269|PubMed:22801543}.
CC   -!- TISSUE SPECIFICITY: Widely expressed, with high levels of
CC       expression in heart and lung. {ECO:0000269|PubMed:23770608}.
CC   -!- DEVELOPMENTAL STAGE: Expression is cell cycle-dependent, with
CC       highest levels in G2/M phase and lowest in G1.
CC       {ECO:0000269|PubMed:22801543}.
CC   -!- INDUCTION: Up-regulated by serum stimulation.
CC       {ECO:0000269|PubMed:1542570}.
CC   -!- DOMAIN: The CysB motif binds 1 4Fe-4S cluster and is required for
CC       the formation of polymerase complexes. {ECO:0000250}.
CC   -!- DISEASE: Colorectal cancer 10 (CRCS10) [MIM:612591]: A complex
CC       disease characterized by malignant lesions arising from the inner
CC       wall of the large intestine (the colon) and the rectum. Genetic
CC       alterations are often associated with progression from
CC       premalignant lesion (adenoma) to invasive adenocarcinoma. Risk
CC       factors for cancer of the colon and rectum include colon polyps,
CC       long-standing ulcerative colitis, and genetic family history.
CC       {ECO:0000269|PubMed:23263490, ECO:0000269|PubMed:24501277}.
CC       Note=Disease susceptibility is associated with variations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Mandibular hypoplasia, deafness, progeroid features, and
CC       lipodystrophy syndrome (MDPL) [MIM:615381]: An autosomal dominant
CC       systemic disorder characterized by prominent loss of subcutaneous
CC       fat, metabolic abnormalities including insulin resistance and
CC       diabetes mellitus, sclerodermatous skin, and a facial appearance
CC       characterized by mandibular hypoplasia. Sensorineural deafness
CC       occurs late in the first or second decades of life.
CC       {ECO:0000269|PubMed:23770608}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the DNA polymerase type-B family.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/pold1/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M80397; AAA58439.1; -; mRNA.
DR   EMBL; M81735; AAA35768.1; -; mRNA.
DR   EMBL; AY129569; AAM76971.1; -; Genomic_DNA.
DR   EMBL; BC008800; AAH08800.1; -; mRNA.
DR   CCDS; CCDS12795.1; -.
DR   PIR; A41618; A41618.
DR   RefSeq; NP_001243778.1; NM_001256849.1.
DR   RefSeq; NP_002682.2; NM_002691.3.
DR   RefSeq; XP_011525340.1; XM_011527038.1.
DR   RefSeq; XP_016882370.1; XM_017026881.1.
DR   UniGene; Hs.279413; -.
DR   ProteinModelPortal; P28340; -.
DR   SMR; P28340; -.
DR   BioGrid; 111420; 63.
DR   IntAct; P28340; 35.
DR   MINT; MINT-1414678; -.
DR   STRING; 9606.ENSP00000406046; -.
DR   BindingDB; P28340; -.
DR   ChEMBL; CHEMBL2735; -.
DR   iPTMnet; P28340; -.
DR   PhosphoSitePlus; P28340; -.
DR   BioMuta; POLD1; -.
DR   DMDM; 50403732; -.
DR   EPD; P28340; -.
DR   MaxQB; P28340; -.
DR   PaxDb; P28340; -.
DR   PeptideAtlas; P28340; -.
DR   PRIDE; P28340; -.
DR   DNASU; 5424; -.
DR   Ensembl; ENST00000440232; ENSP00000406046; ENSG00000062822.
DR   Ensembl; ENST00000599857; ENSP00000473052; ENSG00000062822.
DR   GeneID; 5424; -.
DR   KEGG; hsa:5424; -.
DR   UCSC; uc002psb.6; human.
DR   CTD; 5424; -.
DR   DisGeNET; 5424; -.
DR   GeneCards; POLD1; -.
DR   H-InvDB; HIX0202825; -.
DR   HGNC; HGNC:9175; POLD1.
DR   HPA; CAB004375; -.
DR   HPA; HPA046524; -.
DR   MalaCards; POLD1; -.
DR   MIM; 174761; gene.
DR   MIM; 612591; phenotype.
DR   MIM; 615381; phenotype.
DR   neXtProt; NX_P28340; -.
DR   OpenTargets; ENSG00000062822; -.
DR   Orphanet; 363649; Mandibular hypoplasia-deafness-progeroid syndrome.
DR   PharmGKB; PA33496; -.
DR   eggNOG; KOG0968; Eukaryota.
DR   eggNOG; COG0417; LUCA.
DR   GeneTree; ENSGT00560000077365; -.
DR   HOGENOM; HOG000036616; -.
DR   HOVERGEN; HBG051395; -.
DR   InParanoid; P28340; -.
DR   KO; K02327; -.
DR   PhylomeDB; P28340; -.
DR   TreeFam; TF352785; -.
DR   BRENDA; 2.7.7.7; 2681.
DR   Reactome; R-HSA-110314; Recognition of DNA damage by PCNA-containing replication complex.
DR   Reactome; R-HSA-174411; Polymerase switching on the C-strand of the telomere.
DR   Reactome; R-HSA-174414; Processive synthesis on the C-strand of the telomere.
DR   Reactome; R-HSA-174417; Telomere C-strand (Lagging Strand) Synthesis.
DR   Reactome; R-HSA-174437; Removal of the Flap Intermediate from the C-strand.
DR   Reactome; R-HSA-2564830; Cytosolic iron-sulfur cluster assembly.
DR   Reactome; R-HSA-5358565; Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha).
DR   Reactome; R-HSA-5358606; Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta).
DR   Reactome; R-HSA-5651801; PCNA-Dependent Long Patch Base Excision Repair.
DR   Reactome; R-HSA-5656169; Termination of translesion DNA synthesis.
DR   Reactome; R-HSA-5685942; HDR through Homologous Recombination (HRR).
DR   Reactome; R-HSA-5696397; Gap-filling DNA repair synthesis and ligation in GG-NER.
DR   Reactome; R-HSA-5696400; Dual Incision in GG-NER.
DR   Reactome; R-HSA-6782135; Dual incision in TC-NER.
DR   Reactome; R-HSA-6782210; Gap-filling DNA repair synthesis and ligation in TC-NER.
DR   Reactome; R-HSA-69091; Polymerase switching.
DR   Reactome; R-HSA-69166; Removal of the Flap Intermediate.
DR   Reactome; R-HSA-69183; Processive synthesis on the lagging strand.
DR   GeneWiki; POLD1; -.
DR   GenomeRNAi; 5424; -.
DR   PMAP-CutDB; P28340; -.
DR   PRO; PR:P28340; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   Bgee; ENSG00000062822; -.
DR   CleanEx; HS_POLD1; -.
DR   ExpressionAtlas; P28340; baseline and differential.
DR   Genevisible; P28340; HS.
DR   GO; GO:0016235; C:aggresome; IDA:HPA.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0043625; C:delta DNA polymerase complex; IBA:GO_Central.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0000109; C:nucleotide-excision repair complex; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0008296; F:3'-5'-exodeoxyribonuclease activity; IBA:GO_Central.
DR   GO; GO:0051539; F:4 iron, 4 sulfur cluster binding; IEA:UniProtKB-KW.
DR   GO; GO:0003682; F:chromatin binding; IDA:UniProtKB.
DR   GO; GO:0003684; F:damaged DNA binding; IDA:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; IDA:UniProtKB.
DR   GO; GO:0003887; F:DNA-directed DNA polymerase activity; IMP:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0000166; F:nucleotide binding; IEA:InterPro.
DR   GO; GO:0006287; P:base-excision repair, gap-filling; IDA:UniProtKB.
DR   GO; GO:0034644; P:cellular response to UV; IDA:UniProtKB.
DR   GO; GO:0042769; P:DNA damage response, detection of DNA damage; TAS:Reactome.
DR   GO; GO:0006266; P:DNA ligation; TAS:Reactome.
DR   GO; GO:0006281; P:DNA repair; TAS:ProtInc.
DR   GO; GO:0006260; P:DNA replication; IMP:UniProtKB.
DR   GO; GO:0045004; P:DNA replication proofreading; IBA:GO_Central.
DR   GO; GO:0000731; P:DNA synthesis involved in DNA repair; IDA:UniProtKB.
DR   GO; GO:0055089; P:fatty acid homeostasis; IMP:UniProtKB.
DR   GO; GO:0006298; P:mismatch repair; TAS:Reactome.
DR   GO; GO:0006297; P:nucleotide-excision repair, DNA gap filling; IMP:UniProtKB.
DR   GO; GO:0033683; P:nucleotide-excision repair, DNA incision; TAS:Reactome.
DR   GO; GO:0006296; P:nucleotide-excision repair, DNA incision, 5'-to lesion; TAS:Reactome.
DR   GO; GO:0009411; P:response to UV; TAS:ProtInc.
DR   GO; GO:0000723; P:telomere maintenance; TAS:Reactome.
DR   GO; GO:0000722; P:telomere maintenance via recombination; TAS:Reactome.
DR   GO; GO:0006283; P:transcription-coupled nucleotide-excision repair; TAS:Reactome.
DR   GO; GO:0019985; P:translesion synthesis; TAS:Reactome.
DR   Gene3D; 3.30.420.10; -; 1.
DR   Gene3D; 3.90.1600.10; -; 1.
DR   InterPro; IPR006172; DNA-dir_DNA_pol_B.
DR   InterPro; IPR017964; DNA-dir_DNA_pol_B_CS.
DR   InterPro; IPR006133; DNA-dir_DNA_pol_B_exonuc.
DR   InterPro; IPR006134; DNA-dir_DNA_pol_B_multi_dom.
DR   InterPro; IPR023211; DNA_pol_palm_dom.
DR   InterPro; IPR012337; RNaseH-like_dom.
DR   InterPro; IPR025687; Znf-C4pol.
DR   Pfam; PF00136; DNA_pol_B; 1.
DR   Pfam; PF03104; DNA_pol_B_exo1; 1.
DR   Pfam; PF14260; zf-C4pol; 1.
DR   PRINTS; PR00106; DNAPOLB.
DR   SMART; SM00486; POLBc; 1.
DR   SUPFAM; SSF53098; SSF53098; 1.
DR   PROSITE; PS00116; DNA_POLYMERASE_B; 1.
PE   1: Evidence at protein level;
KW   4Fe-4S; Complete proteome; Disease mutation; DNA damage; DNA excision;
KW   DNA repair; DNA replication; DNA-binding; DNA-directed DNA polymerase;
KW   Exonuclease; Hydrolase; Iron; Iron-sulfur; Metal-binding; Methylation;
KW   Nuclease; Nucleotidyltransferase; Nucleus; Polymorphism;
KW   Reference proteome; Transferase; Zinc; Zinc-finger.
FT   CHAIN         1   1107       DNA polymerase delta catalytic subunit.
FT                                /FTId=PRO_0000046442.
FT   ZN_FING    1012   1029       CysA-type.
FT   MOTIF         4     19       Nuclear localization signal.
FT                                {ECO:0000255}.
FT   MOTIF      1058   1076       CysB motif.
FT   METAL      1012   1012       Zinc. {ECO:0000250}.
FT   METAL      1015   1015       Zinc. {ECO:0000250}.
FT   METAL      1026   1026       Zinc. {ECO:0000250}.
FT   METAL      1029   1029       Zinc. {ECO:0000250}.
FT   METAL      1058   1058       Iron-sulfur (4Fe-4S). {ECO:0000250}.
FT   METAL      1061   1061       Iron-sulfur (4Fe-4S). {ECO:0000250}.
FT   METAL      1071   1071       Iron-sulfur (4Fe-4S). {ECO:0000250}.
FT   METAL      1076   1076       Iron-sulfur (4Fe-4S). {ECO:0000250}.
FT   MOD_RES      19     19       Omega-N-methylarginine.
FT                                {ECO:0000244|PubMed:24129315}.
FT   VARIANT       5      5       R -> W (in dbSNP:rs9282830).
FT                                /FTId=VAR_048878.
FT   VARIANT      19     19       R -> H (in dbSNP:rs3218773).
FT                                {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_019340.
FT   VARIANT      21     21       G -> C (in dbSNP:rs9282831).
FT                                /FTId=VAR_048879.
FT   VARIANT      30     30       R -> W (in dbSNP:rs3218772).
FT                                {ECO:0000269|PubMed:1722322,
FT                                ECO:0000269|Ref.3}.
FT                                /FTId=VAR_016146.
FT   VARIANT     119    119       R -> H (in dbSNP:rs1726801).
FT                                {ECO:0000269|PubMed:1542570,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|Ref.3}.
FT                                /FTId=VAR_019341.
FT   VARIANT     145    145       A -> D (found in a colorectal sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:23263490}.
FT                                /FTId=VAR_069333.
FT   VARIANT     173    173       S -> N (in dbSNP:rs1726803).
FT                                {ECO:0000269|PubMed:1542570,
FT                                ECO:0000269|Ref.3}.
FT                                /FTId=VAR_019342.
FT   VARIANT     177    177       R -> H (in dbSNP:rs3218750).
FT                                {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_019343.
FT   VARIANT     347    347       P -> L (in dbSNP:rs2230243).
FT                                /FTId=VAR_048880.
FT   VARIANT     461    461       Q -> H (found in a colorectal sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:23263490}.
FT                                /FTId=VAR_069334.
FT   VARIANT     474    474       L -> P (in CRCS10; dbSNP:rs587777627).
FT                                {ECO:0000269|PubMed:24501277}.
FT                                /FTId=VAR_071966.
FT   VARIANT     478    478       S -> N (in CRCS10; associated with
FT                                disease susceptibility;
FT                                dbSNP:rs397514632).
FT                                {ECO:0000269|PubMed:23263490}.
FT                                /FTId=VAR_069335.
FT   VARIANT     605    605       Missing (in MDPL; the mutant enzyme lacks
FT                                DNA polymerase ability; has decreased
FT                                exonuclease activity; can bind DNA but is
FT                                unable to interact with and incorporate
FT                                dNTPs). {ECO:0000269|PubMed:23770608}.
FT                                /FTId=VAR_070231.
FT   VARIANT     787    787       P -> L (found in a colorectal sample;
FT                                somatic mutation; dbSNP:rs199783227).
FT                                {ECO:0000269|PubMed:23263490}.
FT                                /FTId=VAR_069336.
FT   VARIANT     808    808       R -> H (found in a colorectal sample;
FT                                somatic mutation; dbSNP:rs771700024).
FT                                {ECO:0000269|PubMed:23263490}.
FT                                /FTId=VAR_069337.
FT   VARIANT     849    849       R -> H (in dbSNP:rs3218775).
FT                                {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_019344.
FT   VARIANT     864    864       A -> T (found in a colorectal sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:23263490}.
FT                                /FTId=VAR_069338.
FT   VARIANT    1086   1086       R -> Q (in dbSNP:rs3219457).
FT                                {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_019345.
FT   MUTAGEN     402    402       D->A: Loss of exonuclease activity. No
FT                                effect on DNA polymerase activity.
FT                                {ECO:0000269|PubMed:19074196,
FT                                ECO:0000269|PubMed:20334433}.
FT   CONFLICT    472    472       Y -> H (in Ref. 1; AAA58439).
FT                                {ECO:0000305}.
FT   CONFLICT    776    776       R -> G (in Ref. 2; AAA35768).
FT                                {ECO:0000305}.
SQ   SEQUENCE   1107 AA;  123631 MW;  9D04D34AB4AEE810 CRC64;
     MDGKRRPGPG PGVPPKRARG GLWDDDDAPR PSQFEEDLAL MEEMEAEHRL QEQEEEELQS
     VLEGVADGQV PPSAIDPRWL RPTPPALDPQ TEPLIFQQLE IDHYVGPAQP VPGGPPPSRG
     SVPVLRAFGV TDEGFSVCCH IHGFAPYFYT PAPPGFGPEH MGDLQRELNL AISRDSRGGR
     ELTGPAVLAV ELCSRESMFG YHGHGPSPFL RITVALPRLV APARRLLEQG IRVAGLGTPS
     FAPYEANVDF EIRFMVDTDI VGCNWLELPA GKYALRLKEK ATQCQLEADV LWSDVVSHPP
     EGPWQRIAPL RVLSFDIECA GRKGIFPEPE RDPVIQICSL GLRWGEPEPF LRLALTLRPC
     APILGAKVQS YEKEEDLLQA WSTFIRIMDP DVITGYNIQN FDLPYLISRA QTLKVQTFPF
     LGRVAGLCSN IRDSSFQSKQ TGRRDTKVVS MVGRVQMDML QVLLREYKLR SYTLNAVSFH
     FLGEQKEDVQ HSIITDLQNG NDQTRRRLAV YCLKDAYLPL RLLERLMVLV NAVEMARVTG
     VPLSYLLSRG QQVKVVSQLL RQAMHEGLLM PVVKSEGGED YTGATVIEPL KGYYDVPIAT
     LDFSSLYPSI MMAHNLCYTT LLRPGTAQKL GLTEDQFIRT PTGDEFVKTS VRKGLLPQIL
     ENLLSARKRA KAELAKETDP LRRQVLDGRQ LALKVSANSV YGFTGAQVGK LPCLEISQSV
     TGFGRQMIEK TKQLVESKYT VENGYSTSAK VVYGDTDSVM CRFGVSSVAE AMALGREAAD
     WVSGHFPSPI RLEFEKVYFP YLLISKKRYA GLLFSSRPDA HDRMDCKGLE AVRRDNCPLV
     ANLVTASLRR LLIDRDPEGA VAHAQDVISD LLCNRIDISQ LVITKELTRA ASDYAGKQAH
     VELAERMRKR DPGSAPSLGD RVPYVIISAA KGVAAYMKSE DPLFVLEHSL PIDTQYYLEQ
     QLAKPLLRIF EPILGEGRAE AVLLRGDHTR CKTVLTGKVG GLLAFAKRRN CCIGCRTVLS
     HQGAVCEFCQ PRESELYQKE VSHLNALEER FSRLWTQCQR CQGSLHEDVI CTSRDCPIFY
     MRKKVRKDLE DQEQLLRRFG PPGPEAW
//
